Cassava Sciences Files Lawsuit Against Perpetrators of “Short and Distort” Campaign
November 03, 2022 09:15 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced that it has filed a lawsuit in federal court against...
Cassava Sciences Announces Expansion of Leadership Team
October 27, 2022 09:15 ET
|
Cassava Sciences, Inc.
Chris Cook, A Skilled Litigator, To Join Management Team as General CounselNew Position Is Expected to Be Critical to Operations and Strategic Initiatives AUSTIN, Texas, Oct. 27, 2022 (GLOBE...
Cassava Sciences Announces Initiation of an Open-label Extension Study
October 13, 2022 09:15 ET
|
Cassava Sciences, Inc.
Alzheimer’s Patients Who Complete Participation in a Phase 3 Study of Simufilam are Eligible to Enroll52-week Study of Simufilam 100 mgUp to 1,600 Patients Are Expected to Enroll AUSTIN, Texas,...
Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference
September 08, 2022 09:15 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it has been...
No Evidence of Data Manipulation in Science Publication on Simufilam
August 18, 2022 09:15 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, was recently informed by the Journal of...
Cassava Sciences Reports Second Quarter Financial Results for 2022, Mid-year Corporate Update and Interim Analysis of Open-label Study
August 03, 2022 09:15 ET
|
Cassava Sciences, Inc.
Phase 3 Program - Over 400 Patients Are Now Enrolled in Our Phase 3 Clinical Studies. Open-label Study – Results of an Interim Analysis on the First 100 Patients Who Have Completed at Least 12 Months...
Cassava Sciences Responds to Media Reports
July 27, 2022 13:36 ET
|
Cassava Sciences, Inc.
- In November 2021, Cassava Sciences previously disclosed that certain government agencies had asked for corporate information and at that time, the media widely reported on these prior disclosures. ...
Cassava Sciences Reports First Quarter Financial Results for 2022 and Updates on Phase 3 Clinical Program
May 05, 2022 09:00 ET
|
Cassava Sciences, Inc.
- $209.7 Million Cash and Cash Equivalents at March 31, 2022 – - Over 120 Patients Now Enrolled in Phase 3 Program - AUSTIN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq:...
Cassava Sciences Invited to Participate in B. Riley Securities’ Neuroscience Conference
April 25, 2022 09:00 ET
|
Cassava Sciences, Inc.
- Q&A Session at Conference on Wednesday, April 27th at 1:30PM Eastern - AUSTIN, Texas, April 25, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology...
Webcast Details for Cassava Sciences’ Upcoming Fireside Chat
April 04, 2022 09:00 ET
|
Cassava Sciences, Inc.
– All Stakeholder Are Welcome to Listen by Webcast – – Event To Be Held Tuesday, April 5th, 9am ET – AUSTIN, Texas, April 04, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a...